Enzon Oncaspar
Executive Summary
"Approvable" anticancer agent will be marketed by Rhone- Poulenc Rorer under agreement announced Dec. 8. Enzon will receive $6 mil. in licensing fees and 50% profit share. RPR will establish a specialty sales force dedicated to the PEG-L- asparaginase product. The two companies will also explore indications beyond the expected initial one of acute lymphoblastic leukemia in patients hypersensitive to native L-asparaginase.